Mainz Biomed Partners with Microba Life Sciences
Molecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1283 entries already.
Entries by Thomas Gabrielczyk
DiogenX SA raises 27.5M in Series A financing
/in News/by Thomas GabrielczykFrench pancreatic beta-cell modulator specialist DiogenX SA has raised 27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.
Wacker AG expands biotech business through 100m acquisition
/in News/by Thomas GabrielczykMunich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for 100m.
Neogap Therapeutics A/S partners with Cellerys AG
/in News/by Thomas GabrielczykSwedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial.
Dutch State to sell share capital of Intravacc BV
/in News/by Thomas GabrielczykThe State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Tay Therapeutics in licensing deal with VYNE Therapeutics
/in News/by Thomas GabrielczykTay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
EU to decarbonise aviation sector through green fuel targets
/in News/by Thomas GabrielczykThe European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene.
Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
/in News/by Thomas GabrielczykIn 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated […]
Novartis in US$465m deal with 3B Pharmaceuticals GmbH
/in News/by Thomas GabrielczykTargeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Syngenta partners with Biotalys
/in News/by Thomas GabrielczykSyngenta has announced to leverage Biotalys AGROBODY technology platform to expand its biocontrol pipeline.